Skip to main content
Reviews Wolverine

A flat, gallery-style review of the BPC-157 + TB-500 'Wolverine' blend — the published record on each peptide set down as study plates, with the combination claim and the regulatory-access status read plainly first.

Track 07 · the sources

BPC-157 TB-500 References: The Studies and FDA Sources

Every quantitative claim on this site maps to one of these. Peer-reviewed studies first, audited FDA sources for the regulatory record beneath.

Back to the reviewThe legal-status record

How to read this list

These are the BPC-157 TB-500 references this review draws on. Citations [1]-[8] are the peer-reviewed primary studies and recent reviews behind the mechanism, findings, and dosage pages. Citations [9]-[11] are the audited FDA sources behind the Wolverine legal status and FDA 503A category page; each was verified loading and containing the cited text on May 29, 2026.

Where a constituent has only single-compound or full-length-Thymosin-Beta-4 data, the citation says so. No reference here is offered as evidence for the assembled blend, because the combination literature is empty [6]. The complete entries follow.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Withdrawn nominations for BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; both no longer in Category 2; previous placement effective September 29, 2023; page content current as of April 22, 2026; checked September 2026.) ↗
  10. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2 and the 503A/503B bulks-list framework; verified 2026-05-29.) ↗
  11. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 as bulk drug substances being considered for inclusion on the 503A Bulks List; verified 2026-05-29.) ↗
  12. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  13. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  14. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  15. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗